Retatrutide has no approved label, so every dose figure here traces back to its published Phase 2 obesity trial rather than a prescribing guideline. That trial tested once-weekly subcutaneous doses of 1 mg, 4 mg, 8 mg, and 12 mg with staged dose-escalation over 48 weeks.[1][2]
Reviewed for accuracy · Last reviewed July 7, 2026A typical titration schedule starts low and steps up every 4 weeks:
The titration table below mirrors that stepwise approach: start low and increase every four weeks so the gut has time to adjust. Because retatrutide is still investigational, treat these numbers as a description of what was studied, not a recommendation.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.